HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

type 2C Congenital disorder of glycosylation

Also Known As:
Congenital disorder of glycosylation, type 2C; CDG2C; Congenital Disorder Of Glycosylation, Type IIC; LAD2; Leukocyte Adhesion Deficiency, Type II; Leukocyte adhesion deficiency, type 2; Rambam Hasharon syndrome; Rambam-Hasharon Syndrome
Networked: 261 relevant articles (2 outcomes, 25 trials/studies)

Relationship Network

Disease Context: Research Results

Related Diseases

1. Anaphylaxis (Anaphylactic Shock)
2. Inflammation (Inflammations)
3. Leukemia
4. Rosacea (Acne Rosacea)
5. Hypersensitivity (Allergy)

Experts

1. Theoharides, Theoharis C: 18 articles (12/2019 - 07/2009)
2. Che, Delu: 15 articles (05/2021 - 10/2017)
3. Wang, Jue: 13 articles (11/2021 - 10/2017)
4. Kulka, Marianna: 12 articles (12/2021 - 03/2008)
5. Zhang, Yongjing: 11 articles (11/2021 - 09/2018)
6. Zhang, Tao: 11 articles (12/2020 - 10/2017)
7. He, Langchong: 10 articles (01/2021 - 10/2017)
8. Cao, Jiao: 10 articles (12/2020 - 10/2017)
9. Wang, Nan: 9 articles (06/2022 - 01/2018)
10. Ali, Hydar: 9 articles (01/2021 - 01/2011)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to type 2C Congenital disorder of glycosylation:
1. Interleukin-8 (Interleukin 8)IBA
2. Interleukin-6 (Interleukin 6)IBA
01/01/2012 - "However, Que is more effective than cromolyn in inhibiting IL-8 and TNF release from LAD2 mast cells stimulated by SP. Moreover, Que reduces IL-6 release from hCBMCs in a dose-dependent manner. "
11/07/2023 - "We first optimized the susceptibility of LAD2 cells to IgE-mediated degranulation in HVA and showed that prestimulation with IL-33 and IL-6 significantly increased the LAD2 cells´ responsiveness to allergen stimulation (P<0.01). "
01/01/2022 - "The mast cell line LAD2 was treated with different SP concentrations, and ELISA results showed that the expression of IL-6, IL-17A, IL-23, and TGF-β in the cell supernatant gradually increased with increasing SP concentrations, whereas that of IL-10 decreased. "
03/11/2010 - "Human leukemic cultured LAD2 mast cells and normal human umbilical cord blood-derived cultured mast cells (hCBMCs) were stimulated by HgCl2 (0.1-10 microM) for either 10 min for beta-hexosaminidase release or 24 hr for measuring vascular endothelial growth factor (VEGF) and IL-6 release by ELISA. "
01/01/2023 - "We found that (i) serum intestinal permeability indices and bacterial DNA markedly increased in patients with chronic spontaneous urticaria with nonsedating H1-antihistamine resistance compared with those without (all P < 0.001), and bacterial DNA positively correlated with the degree of inflammation; (ii) IL-6 and TNF-α levels were time- and dose-dependently upregulated in bacterial DNA-stimulated LAD2 cells, which relied on unmethylated CpG in bacterial DNA and Toll-like receptor 9 protein in cells; (iii) Syk knockdown or inhibition of Syk Tyr525/526 phosphorylation blocked bacterial DNA-initiated cytokine production; (iv) Nedd4L interacted with Tyr525/526-phosphorylated Syk, and inhibition of Nedd4L Ser448 phosphorylation induced by bacterial DNA-activated Sgk1 was mandatory for bacterial DNA's proinflammatory property; and (v) Sgk1 suppression showed an inhibitory effect on bacterial DNA-induced inflammation by ensuring Nedd4L-mediated ubiquitination of Tyr525/526-phosphorylated Syk. "
3. Cromolyn Sodium (Cromoglicic Acid)FDA LinkGeneric
4. SesquiterpenesIBA
5. Immunoglobulin E (IgE)IBA
6. CalciumIBA
7. LigandsIBA
8. p-Methoxy-N-methylphenethylamineIBA
9. Peptidoglycan (Murein)IBA
10. CytokinesIBA

Therapies and Procedures

1. Aftercare (After-Treatment)
2. Therapeutics
3. Synchrotrons
4. Sutures (Suture)
5. Ligation